This review suggests that the use of low-dose insulin (0.05 U/kg/h) is appropriate for selected patients with mild-to-moderate DKA, as it reduces the risk of iatrogenic complications such as hypoglycemia and hypokalemia without compromising treatment efficacy. This evidence concerns the gene INS and Hypoglycemia.